Evidence map›Paper›PMID 32900657›Full record

ArticleBiological psychiatry. Cognitive neuroscience and neuroimaging2021

Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression.

Megha M Vasavada, Joana Loureiro, Antoni Kubicki, Ashish Sahib, Benjamin Wade, Gerhard Hellemann, Randall T Espinoza, Eliza Congdon, Katherine L Narr, Amber M Leaver

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Ketamine for Major Depressive Disorder.Current topics in behavioral neurosciences · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Megha M VasavadaAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Joana LoureiroAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Antoni KubickiAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Ashish SahibAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Benjamin WadeAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Gerhard HellemannJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Randall T EspinozaJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Eliza CongdonJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Katherine L NarrAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Amber M LeaverDepartment of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: amber.leaver@northwestern.edu.
University of California, Los Angeles · USNorthwestern University · US

Funding

Perturbation of the treatment resistant depression connectome by fast-acting therapiesU01MH110008 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ESPINOZA, RANDALL, NARR, KATHERINE L · 2016 to 2019
$5.5M
Biomarkers of fast acting therapies in major depressionK24MH102743 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NARR, KATHERINE L · 2014 to 2018
$889k
Structural and Functional Connectivity and Ketamine Therapy for Major DepressionF32MH111193 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VASAVADA, MEGHA M · 2017 to 2019
$190k
NIMH NIH HHS F32 MH111193NIMH NIH HHS K24 MH102743NIMH NIH HHS U01 MH110008
6 · The paper itself

Abstract

backgroundKetamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD). Resting-state functional magnetic resonance imaging studies show disruptions of functional connectivity (FC) between limbic regions and resting-state networks (RSNs) in MDD, including the default mode network, central executive network (CEN), and salience network (SN). Here, we investigated whether serial ketamine treatments change FC between limbic structures and RSNs.

methodsPatients with MDD (n = 44) were scanned at baseline (time 1 [T1]) and 24 hours after the first (T2) and fourth (T3) infusions of ketamine. Healthy control subjects (n = 50) were scanned at baseline, with a subgroup (n = 17) being rescanned at 2 weeks. Limbic regions included the amygdala and hippocampus, and RSNs included the default mode network, CEN, and SN.

resultsKetamine increased right amygdala FC to the right CEN (p = .05), decreased amygdala FC to the left CEN (p = .005) at T2 versus T1 (p = .015), which then increased at T3 versus T2 (p = .002), and decreased left amygdala FC to the SN (p = .016). Decreased left amygdala to SN FC at T2 predicted improvements in anxiety at T3 (p = .006). Ketamine increased right hippocampus FC to the left CEN (p = .001), and this change at T2 predicted decreased anhedonia at T3 (p = .005).

conclusionsKetamine modulates FC between limbic regions and RSNs implicated in MDD. Increases in FC between limbic regions and the CEN suggest that ketamine may be involved in restoring top-down control of emotion processing. FC decreases between the left amygdala and SN suggest that ketamine may ameliorate MDD-related dysconnectivity in these circuits. Early FC changes between limbic regions and RSNs may be predictive of clinical improvements.

Indexed as

KetamineMajor Depressive DisorderBrainDepressionHumansNeural PathwaysKetamineAntidepressant treatmentFunctional connectivityKetamineMajor depressionMood disordersPersonalized medicine

Identifiers

PMID32900657
PMCPMC8629108
OpenAlexW3038241450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.